학술논문
Inhibition of thrombin activatable fibrinolysis inhibitor (TAFI) via DS-1040 to accelerate clot lysis in patients with acute pulmonary embolism: a randomized phase Ib study.
Document Type
Article
Author
Source
Journal of Thrombosis and Haemostasis; 20230101, Issue: Preprints
Subject
Language
ISSN
15387933; 15387836
Abstract
The optimal treatment of intermediate-risk pulmonary embolism (PE) in hemodynamically stable patients remains unknown. Fibrinolytics reduce the risk of hemodynamic deterioration but increase bleeding risk. DS-1040, an inhibitor of thrombin activatable fibrinolysis inhibitor (TAFI), enhances endogenous fibrinolytic activity without increasing bleeding risk in preclinical studies.